Terms: = Breast cancer AND MITF, WS2A, ENSG00000187098, 4286 AND Diagnosis
5 results:
1. Genomic Profiling Aids Classification of Diagnostically Challenging Uterine Mesenchymal Tumors With Myomelanocytic Differentiation.
Selenica P; Conlon N; Gonzalez C; Frosina D; Jungbluth AA; Beets-Tan RGH; Rao MK; Zhang Y; Benayed R; Ladanyi M; Solit DB; Chiang S; Hyman DM; Hensley ML; Soslow RA; Weigelt B; Murali R
Am J Surg Pathol; 2021 Jan; 45(1):77-92. PubMed ID: 32889887
[TBL] [Abstract] [Full Text] [Related]
2. Dedifferentiated Melanoma With Expression of Cytokeratin and GATA3 in a Patient With History of breast Carcinoma.
Alkhasawneh A; Nassri A; John I
Am J Dermatopathol; 2019 Jul; 41(7):502-504. PubMed ID: 30562218
[TBL] [Abstract] [Full Text] [Related]
3. breast cancer suppressor candidate-1 (BCSC-1) is a melanoma tumor suppressor that down regulates mitf.
Anghel SI; Correa-Rocha R; Budinska E; Boligan KF; Abraham S; Colombetti S; Fontao L; Mariotti A; Rimoldi D; Ghanem GE; Fisher DE; Lévy F; Delorenzi M; Piguet V
Pigment Cell Melanoma Res; 2012 Jul; 25(4):482-7. PubMed ID: 22594792
[TBL] [Abstract] [Full Text] [Related]
4. Serum biomarkers for detection of breast cancers: A prospective study.
Mathelin C; Cromer A; Wendling C; Tomasetto C; Rio MC
Breast Cancer Res Treat; 2006 Mar; 96(1):83-90. PubMed ID: 16322896
[TBL] [Abstract] [Full Text] [Related]
5. Role for microphthalmia transcription factor in the diagnosis of metastatic malignant melanoma.
Granter SR; Weilbaecher KN; Quigley C; Fisher DE
Appl Immunohistochem Mol Morphol; 2002 Mar; 10(1):47-51. PubMed ID: 11893035
[TBL] [Abstract] [Full Text] [Related]
